Seattle, WA -- (SBWIRE) -- 11/14/2019 -- Familial Amyloid Cardiomyopathy Treatment Market – Insights
Familial amyloid cardiomyopathy (FAC), also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy, is the aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart. The condition is more prevalent in geriatric population. The protein transthyretin amyloid fibrils infiltrates the myocardium, thereby leading to diastolic dysfunction from restrictive cardiomyopathy. This in turn increases the risk of heart failure. V1221, P24S, V20I, A45T, Gly47Val, I68L, L111M, Glu51Gly, and Gln92Lys are some of the mutations in TTR, which are associated with familial amyloid cardiomyopathy. V1221 is the most common mutation and is substitution of isoleucine for valine at position 122 that occurs in high frequency in African-Americans.

Genetic tests are recommended for detection of TTR gene. FAC is fatal. Some symptoms of FAC include, weight loss, nausea, fatigue, dizziness and collapse, palpitations, abnormal heart rhythms, disrupted sleep, and angina. Inherited transthyretin gene alteration leads to formation of transthyretin protein in the body, thereby causing FAC. Gene alteration changes the sequence of body proteins. Autosomal dominant allele inherit FAC. The condition can pass to offspring from any one of the parent as only one copy of mutated gene is sufficient for progression of the condition. FAC can lead to heart failure. For instance, according to Amyloidosis Foundation (AF), FAC is a rare disease, affecting 1 per 100,000 population.

Download A Readymade Sample PDF Copy: https://www.coherentmarketinsights.com/insight/request-sample/684

Familial Amyloid Cardiomyopathy Treatment Market: Drivers
Increasing product approval and launch activities is expected to boost growth of the global familial amyloid cardiomyopathy treatment market. For instance, in 2013, the European Medicines Agency approved tafamids (Vyndaqel), a drug that reduces development of FAC.

Familial Amyloid Cardiomyopathy Treatment Market: Regional Analysis
Increasing TTR mutation is expected to boost growth of the market in Europe. For instance, according to BioMed Central journal, March 2017, people in Europe had the highest number of TTR mutations, followed by East Asia, North America, Central-South Asia, and Africa.

Familial Amyloid Cardiomyopathy Treatment Market: Competitive Landscape
Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in June 2017, the U.S. Food and Drug Administration (FDA) granted fast track designation to Pfizer's tafamidis, an investigational drug for the treatment of FAC. Tafamidis, with trade name VYNDAQEL, was first approved in Europe.

Major players operating the global familial amyloid cardiomyopathy treatment market include, Ionis Pharmaceuticals, Inc., AstraZeneca plc., Pfizer Inc., SOM Innovation Biotech, S.L., and Valeant Pharmaceuticals International, Inc.

Get Customized Report as per your Need: https://www.coherentmarketinsights.com/insight/request-customization/684

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.